Literature DB >> 16168285

Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure.

Wolfram Doehner1, Mathias Rauchhaus, Piotr Ponikowski, Ian F Godsland, Stephan von Haehling, Darlington O Okonko, Francisco Leyva, Anthony J Proudler, Andrew J S Coats, Stefan D Anker.   

Abstract

OBJECTIVES: The aim of this study was to determine the significance of insulin resistance as an independent risk factor for impaired prognosis in patients with chronic heart failure (CHF).
BACKGROUND: In CHF, impaired insulin sensitivity (S(I)) indicates abnormal energy metabolism and is related to decreased exercise capacity and muscle fatigue. The relationship between insulin resistance (i.e., low S(I)) and survival in patients with CHF has not been established.
METHODS: We prospectively studied 105 male patients with CHF due to ischemic (63%) or non-ischemic (37%) etiology. All patients were in clinically stable condition (age 62 +/- 1 year, New York Heart Association [NYHA] functional class 2.6 +/- 0.1, left ventricular ejection fraction [LVEF] 28 +/- 2%, peak oxygen uptake [Vo(2)] 18.2 +/- 0.7 ml/kg/min). Insulin sensitivity was assessed from glucose and insulin dynamic profiles during an intravenous glucose tolerance test using the minimal model technique.
RESULTS: During a mean follow-up period of 44 +/- 4 months, 53 patients (50%) died. Patients with S(I) below the median value (median: 1.82 min(-1) x microU x ml(-1).10(4); n = 52) had worse survival (at two years 61% [range 47% to 74%]) than patients with S(I) above the median value (n = 53; at two years 83% [range 73% to 93%]; risk ratio [RR] 0.38, 95% confidence interval [CI] 0.21 to 0.67; p = 0.001). Both patient groups were similar in terms of age, NYHA functional class, and body composition parameters (dual-energy X-ray absorptiometric scan; p > 0.2), but patients with a lower S(I) had a lower LVEF (24 +/- 2% vs. 33 +/- 3%) and peak Vo(2) (16.8 +/- 1.0 ml/kg/min vs. 19.7 +/- 1.0 ml/kg/min; both p < 0.05). On univariate Cox analysis, higher S(I) predicted better survival (RR 0.56, 95% CI 0.35 to 0.89; p = 0.015). On stepwise multivariate analysis, S(I) predicted mortality independently of other variables.
CONCLUSIONS: In patients with CHF, lower S(I) relates to higher mortality, independent of body composition and established prognosticators. Impaired S(I) may have implications in the pathophysiology of CHF disease progression. Therapeutically targeting impaired insulin sensitivity may potentially be beneficial in patients with CHF.

Entities:  

Mesh:

Year:  2005        PMID: 16168285     DOI: 10.1016/j.jacc.2005.02.093

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  79 in total

Review 1.  Glutamate synthase: a fascinating pathway from L-glutamine to L-glutamate.

Authors:  R H H van den Heuvel; B Curti; M A Vanoni; A Mattevi
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

Review 2.  Hypothalamic mechanisms in cachexia.

Authors:  Aaron J Grossberg; Jarrad M Scarlett; Daniel L Marks
Journal:  Physiol Behav       Date:  2010-03-25

3.  Multiphasic Regulation of Systemic and Peripheral Organ Metabolic Responses to Cardiac Hypertrophy.

Authors:  Chong Wee Liew; Shanshan Xu; Xuerong Wang; Maximilian McCann; Hyerim Whang Kong; Andrew C Carley; Jingbo Pang; Giamila Fantuzzi; J Michael O'Donnell; E Douglas Lewandowski
Journal:  Circ Heart Fail       Date:  2017-04       Impact factor: 8.790

4.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension.

Authors:  Meredith E Pugh; Ivan M Robbins; Todd W Rice; James West; John H Newman; Anna R Hemnes
Journal:  J Heart Lung Transplant       Date:  2011-04-13       Impact factor: 10.247

5.  Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices.

Authors:  Nir Uriel; Yoshifumi Naka; Paolo C Colombo; Maryjane Farr; Sang-Woo Pak; Vlad Cotarlan; Jeanine B Albu; Dympna Gallagher; Donna Mancini; Henry N Ginsberg; Ulrich P Jorde
Journal:  Eur J Heart Fail       Date:  2010-11-23       Impact factor: 15.534

6.  Beta blockers and glucose metabolism in chronic heart failure: friend or foe?

Authors:  W Doehner; S D Anker
Journal:  Clin Res Cardiol       Date:  2008-01       Impact factor: 5.460

7.  Insulin resistance in pulmonary arterial hypertension.

Authors:  R T Zamanian; G Hansmann; S Snook; D Lilienfeld; K M Rappaport; G M Reaven; M Rabinovitch; R L Doyle
Journal:  Eur Respir J       Date:  2008-12-01       Impact factor: 16.671

Review 8.  Adiponectin: key role and potential target to reverse energy wasting in chronic heart failure.

Authors:  An M Van Berendoncks; Anne Garnier; Renée Ventura-Clapier; Viviane M Conraads
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

Review 9.  Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure?

Authors:  Wolfram Doehner
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

Review 10.  Insulin resistance protects the heart from fuel overload in dysregulated metabolic states.

Authors:  Heinrich Taegtmeyer; Christophe Beauloye; Romain Harmancey; Louis Hue
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-04       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.